Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Sept. 6 — Final guidance intended to provide more clarity for drugmakers and safety-net providers participating in the federal 340B drug discount program is moving closer to release.
The White House Office of Management and Budget started its review Sept. 1 of the final guidance document (RIN:0906-AB08 ), according to the OMB's reginfo.gov website. The Department of Health and Human Services released the proposed version of what it calls the omnibus guidance document in August 2015 (13 PLIR 1249, 8/28/15). The 340B program helps safety-net providers obtain discounted drugs.
The guidance would define who is considered a patient for purposes of the 340B program. The guidance also covers drug company responsibilities, such as procedures for issuing credits and refunds. Other subjects covered in the guidance are the HHS's audit of a covered entity, the HHS's audit of a manufacturer and a manufacturer's audit of a covered entity.
The drug industry generally supports the guidance because it says more clarity is needed for the 340B program, particularly for the definition of patient. However, safety-net providers have concerns with the guidance because they say it could limit their ability to serve the poor by putting additional restrictions on drug discounts.
The Health Resources and Services Administration (HRSA), the part of the HHS that administers the program, said in August 2015 that it was “proposing this omnibus guidance to provide increased clarity in the marketplace for all 340B Program stakeholders and strengthen HHS’s ability to administer the 340B Program effectively.”
340B Health, a group that represents health-care providers receiving discounts in the program, said in a Sept. 2 statement provided to Bloomberg BNA that it is “very concerned about key aspects of the proposed mega-guidance which could have a devastating impact on safety-net hospitals' ability to serve the poor.”
“Almost two-thirds of the comments received by HRSA [on the proposed guidance] were from hospitals and we are hopeful that the agency has taken their position into account,” 340B Health said. “In addition, research shows that although 340B DSH [disproportionate share hospital] hospitals only account for about one third of all hospitals, they provide nearly 60 percent of all uncompensated care. They also provide twice as much care to poor patients, patients of color and the disabled.”
340B Health also said “rural hospitals are already struggling to survive and any additional restrictions on accessing pharmaceutical discounts would be a major blow to them and their patients.”
To contact the reporter on this story: Bronwyn Mixer in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The proposed version of the omnibus guidance document is at http://op.bna.com.s3.amazonaws.com/hl.nsf/r%3FOpen%3dbbrk-9zsjjy.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)